Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Human Papillomavirus Infections Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women With HPV16 or 18 Infection of the Cervix

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03610581
• Other study ID #: CR108458
• Secondary ID: 2018-000200-41VA
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: September 27, 2018
• Est. completion date: October 15, 2020

Study information

• Verified date: November 2021
• Source: Janssen Vaccines & Prevention B.V.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to assess safety and reactogenicity of the 3 vaccine regimens.

Description:

This study is part of a vaccine program which aims to generate a therapeutic vaccine for women with HPV types 16 or 18 infection, with a focus on early disease interception. The study consists of 3 periods: Screening period of up to 42 days (6 weeks), followed by prime and boost immunizations and follow-up visits up to 12 months after the first vaccination. Evaluation of the safety/reactogenicity of the vaccine regimens will include physical assessment by study-site personnel, participant reports on signs and symptoms and laboratory assessments following vaccinations. Immunogenicity and Virology/Histology assessments will also be performed.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: October 15, 2020
• Est. primary completion date: October 15, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Willing and able to adhere to the prohibitions and restrictions specified in this protocol

• Must have an human papillomavirus (HPV) type 16 or 18 infection of the cervix as determined by a qualitative PCR test within 8 weeks prior to screening or at the time of screening. Available history of high-risk (HR)-HPV positivity and HPV16 or HPV18 positivity positivity will be recorded

• Must have a recent colposcopy result (with a maximum of 12 months old at screening); in case a colposcopy has not been performed before, it will be done as screening procedure

• Contraceptive (birth control) use by participants should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies

• Agrees not to donate blood until 3 months after receiving the last dose of study vaccine

Exclusion Criteria:

• In case cytology results are available, participant has current or history of high-grade squamous intraepithelial lesion (HSIL), adenocarcinoma in situ (AIS) or any high-grade vulvar, vaginal or anal intraepithelial neoplasia

• Current or history of cervical intraepithelial neoplasia (CIN)2+ or cervical cancer

• Confirmed co-infection with both HPV16 and HPV18

• History of an underlying clinically significant acute or chronic medical condition, other than infection with HPV, or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

• Tests positive for human immunodeficiency virus (HIV) at screening

• Chronic active hepatitis B or hepatitis C infection, verified at screening by hepatitis B surface antigen or anti-hepatitis C virus antibody, respectively

• Vaginal atrophy with or without topical hormonal therapies or systemic selective estrogen receptor modulators

• Exposed to at least 1 dose of an HPV prophylactic vaccine or participant has participated in the past in another preventive or therapeutic HPV vaccine study

• Clinically significant gynecological abnormalities that could, in the judgment of the investigator, interfere with study evaluation (for example [e.g.], prolapse, myoma, fibroid, hysterectomy)

• Symptomatic vaginal or genital infection (including genital herpes) as confirmed by physician or investigator

Related Conditions & MeSH terms

• Communicable Diseases
• Human Papillomavirus Infections
• Infections
• Papillomavirus Infections

Intervention

Biological:
• Ad26.HPV16
Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
• Ad26.HPV18
Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
• MVA.HPV16/18
Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
• Placebo
Participants will receive matched placebo as a solution for intramuscular injection.

Locations

Country	Name	City	State
Belgium	UZ Leuven	Leuven
United States	Doral Medical Research	Doral	Florida
United States	Clinical Physiology Associates	Fort Myers	Florida
United States	University of Iowa Hospital	Iowa City	Iowa
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	VGR & NOCCR - Knoxville	Knoxville	Tennessee
United States	Medpharmics, LLC	Metairie	Louisiana
United States	Florida Research Center Inc.	Miami	Florida
United States	San Marcus Research Clinic, Inc.	Miami Lakes	Florida
United States	Columbia University Medical Center	New York	New York
United States	Heartland Research Associates, LLC	Newton	Kansas
United States	Meridian Clinical Research, LLC	Norfolk	Nebraska

Sponsors (2)

Lead Sponsor	Collaborator
Janssen Vaccines & Prevention B.V.	Bavarian Nordic

Countries where clinical trial is conducted

United States,  Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Solicited Local Adverse Events (AEs)	Number of participants with solicited local AEs were reported. Solicited local AE's included pain/tenderness, erythema, and induration/swelling.	Up to 7 days after each vaccination (Up to Day 64)
Primary	Number of Participants With Solicited Systemic AEs	Number of participants with solicited systemic AEs were reported. Solicited systemic AEs included headache, fatigue, myalgia, arthralgia, chills, and fever.	Up to 7 days after each vaccination (Up to Day 64)
Primary	Number of Participants With Unsolicited AEs	Number of participants with unsolicited AEs were reported. Unsolicited AEs included all AEs for which the participant was not specifically questioned in the participant diary.	28 days after each vaccination (Up to Day 85)
Primary	Number of Participants With Serious Adverse Events (SAEs)	Number of participants with SAEs were reported. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.	Up to 12 months after the first vaccination (target visit Day 366)
Secondary	Percentage of Participants With Human Papillomavirus (HPV)-Specific CD4+ T-cell Responses: Interferon (IFN)g+	Percentage of participants with HPV-Specific CD4+ T-cell responses for IFNg+ to peptide pools were reported. Cellular immunogenicity was measured by intracellular cytokine staining (ICS), allowing characterization of individual CD4 and CD8 T cell immune responses to vaccination. The different peptide pools for HPV16 or HPV 18 were: E2, E6/E7 and combined (E2 and E6/E7 both).	Day 57, Day 78, Day 239, and Day 366
Secondary	Percentage of Participants With HPV-Specific CD4+ T-cell Responses: Interleukin (IL)2+	Percentage of participants with HPV-Specific CD4+ T-cell responses for IL2+ were reported. Cellular immunogenicity was measured by intracellular cytokine staining (ICS), allowing characterization of individual CD4 and CD8 T cell immune responses to vaccination. The different peptide pools for HPV16 or HPV 18 were: E2, E6/E7 and combined (E2 and E6/E7 both).	Day 57, Day 78, Day 239, and Day 366
Secondary	Percentage of Participants With HPV-Specific CD4+ T-cell Responses: Tumor Necrosis Factor (TNF)a+	Percentage of participants with HPV-Specific CD4+ T-cell responses for TNF a+ were reported. Cellular immunogenicity was measured by intracellular cytokine staining (ICS), allowing characterization of individual CD4 and CD8 T cell immune responses to vaccination. The different peptide pools for HPV16 or HPV 18 were: E2, E6/E7 and combined (E2 and E6/E7 both).	Day 57, Day 78, Day 239, and Day 366
Secondary	Percentage of Participants With HPV-Specific CD8+ T-cell Responses: IFNg+	Percentage of participants with HPV-Specific CD8+ T-cell responses for IFNg+ were reported. Cellular immunogenicity was measured by intracellular cytokine staining (ICS), allowing characterization of individual CD4 and CD8 T cell immune responses to vaccination. The different peptide pools for HPV16 or HPV 18 were: E2, E6/E7 and combined (E2 and E6/E7 both).	Day 57, Day 78, Day 239, and Day 366
Secondary	Percentage of Participants With HPV-Specific CD8+ T-cell Responses: IL2+	Percentage of participants with HPV-Specific CD8+ T-cell responses for IL2+ were reported. Cellular immunogenicity was measured by intracellular cytokine staining (ICS), allowing characterization of individual CD4 and CD8 T cell immune responses to vaccination. The different peptide pools for HPV16 or HPV 18 were: E2, E6/E7 and combined (E2 and E6/E7 both).	Day 57, Day 78, Day 239, and Day 366
Secondary	Percentage of Participants With HPV-Specific CD8+ T-cell Responses: TNFa+	Percentage of participants with HPV-Specific CD8+ T-cell responses for TNFa+ were reported. Cellular immunogenicity was measured by intracellular cytokine staining (ICS), allowing characterization of individual CD4 and CD8 T cell immune responses to vaccination. The different peptide pools for HPV16 or HPV 18 were: E2, E6/E7 and combined (E2 and E6/E7 both).	Day 57, Day 78, Day 239, and Day 366